TomoxetineHcl 1kg
2 Inquiries
83015-26-3
Pharmaceutical Grade
95%
shanghai
Dideu
1kg/bag
Yes
2025-05-11
Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference(R)-Tomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.
Solid
Atomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. It has a role as an adrenergic uptake inhibitor, an antidepressant, a xenobiotic and an environmental contaminant. It is an aromatic ether, a secondary amino compound and a member of toluenes.|Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which is a limiting factor associated with the use of stimulant medications such as [DB00422], [DB01576], and [DB01255]. Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT), and blocks the N-methyl-d-aspartate (NMDA) receptor, indicating a role for the glutamatergic system in the pathophysiology of ADHD. Long-acting formulations of psychostimulants (such as [DB00422], [DB01576], and [DB01255]) are typically considered the most effective and first-line treatment for ADHD in adults and children as recommended by CADDRA (Canadian ADHD Resource Alliance). However, these stimulant medications are limited by dose-related side effects and concerns of abuse. Many contain a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. In particular, increased dopamine in key areas caused by these stimulant medications is associated with their reinforcing and addictive properties, and even amplifies the potency and reinforcing effects of other drugs of abuse such as amphetamines, making ADHD sufferers more susceptible to their addictive effects. Concerns about abuse potential have spurred research into medications with fewer effects on DA and the use of non-stimulant ADHD medications including atomoxetine, [DB00745] and [DB01018]. The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of ADHD.|Atomoxetine is a Norepinephrine Reuptake Inhibitor. The mechanism of action of atomoxetine is as a Norepinephrine Uptake Inhibitor.|Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder. Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury.|A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.Basic Info-
Product Name:
Atomoxetine
Other Name:Benzenepropanamine,N-methyl-γ-(2-methylphenoxy)-,(γR)-;Benzenepropanamine,N-methyl-γ-(2-methylphenoxy)-,(R)-;(γR)-N-Methyl-γ-(2-methylphenoxy)benzenepropanamine;Tomoxetine;(-)-Tomoxetine;Atomoxetine;(R)-Tomoxetine;(R)-Atomoxetine
CAS No.:83015-26-3
Molecular Formula:C17H21NO
InChIKeys:InChIKey=VHGCDTVCOLNTBX-QGZVFWFLSA-N
Molecular Weight:255.355
Exact Mass:255.35
EC Number:1533716-785-6
UNII:ASW034S0B8
DSSTox ID:DTXSID9044297
ATC Code:N06BA09|N - Nervous system
HScode:2922299090
Categories:
Characteristics-
PSA:
21.3
XLogP3:3.9
Appearance:Solid
Density:1.0±0.1 g/cm3
Melting Point:161-165 ºC
Boiling Point:389.0±37.0 °C at 760 mmHg
Flash Point:164.1±16.0 °C
Refractive Index:1.552
Water Solubility:3.90e-03 g/L
Storage Conditions:Store at 25 deg C (77 deg F); excursions permitted to 15 to 30 deg C (59 to 86 deg F).
Vapor Pressure:1.31X10-5 mm Hg at 25 deg C (est)
PKA:10.13None
Henrys Law Constant:Henry's Law constant = 1.13X10-8 atm-cu m/mol at 25 °C (est)
Dissociation Constants:10.13|pKa = 9.80 (secondary amine) (est)
Collision Cross Section:164.2 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]
Experimental Properties:Hydroxyl radical reaction rate constant = 1.22X10-10 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 3, Oral
Serious eye damage, Category 1
Acute toxicity - Category 3, Inhalation
Reproductive toxicity, Category 2
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H301 Toxic if swallowed
H318 Causes serious eye damage
H331 Toxic if inhaled
H361 Suspected of damaging fertility or the unborn child
H411 Toxic to aquatic life with long lasting effects
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
P203 Obtain, read and follow all safety instructions before use.
P273 Avoid release to the environment.
Response P301+P316 IF SWALLOWED: Get emergency medical help immediately.
P321 Specific treatment (see ... on this label).
P330 Rinse mouth.
P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P317 Get medical help.
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P316 Get emergency medical help immediately.
P318 IF exposed or concerned, get medical advice.
P391 Collect spillage.
Storage P405 Store locked up.
P403+P233 Store in a well-ventilated place. Keep container tightly closed.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst
-
Location:
https://www.dideu.com/en/
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
Above 1000
-
Year of Establishment:
2016
Company Certificates-
![Shaanxi Dideu Medichem Co. LtdISO Certificate]( "ISO Certificate")
ISO Certificate
-
![Shaanxi Dideu Medichem Co. LtdREACH]( "REACH")
REACH
">Company Profile -
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
Russia
Atomoxetine
20000 MG Apr 14, 2025
Russia
Atomoxetine
0.1 KG Apr 11, 2025 Post an enquiry for this product
More from this Seller
-
-
![3,5-BIS(4-AMINOPHENOXY)BENZOIC ACID 99% powder to crystal White to Ambe Pharma;Conutrix]( "3,5-BIS(4-AMINOPHENOXY)BENZOIC ACID 99% powder to crystal White to Ambe Pharma;Conutrix")
-
3,5-BIS(4-AMINOPHENOXY)BENZOIC ACID 99% powder to crystal White to Ambe Pharma;Conutrix
Industrial Grade / 99%
-
-
-
![AF710B 10G High Quality Shaanxi Dideu Medichem Co.Ltd]( "AF710B 10G High Quality Shaanxi Dideu Medichem Co.Ltd")
-
AF710B 10G High Quality Shaanxi Dideu Medichem Co.Ltd
Pharmaceutical Grade / 99%
-
-
-
![HYDRAZINE CAS NO.:302-01-2 99% Dideu-1-73875 Dideu]( "HYDRAZINE CAS NO.:302-01-2 99% Dideu-1-73875 Dideu")
-
HYDRAZINE CAS NO.:302-01-2 99% Dideu-1-73875 Dideu
Industrial Grade / 99%
-
